Detalles de la búsqueda
1.
Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018.
Drug Resist Updat
; 37: 17-39, 2018 03.
Artículo
en Inglés
| MEDLINE | ID: mdl-29525636
2.
Safety and Efficacy of Elbasvir/Grazoprevir in Patients With Hepatitis C Virus Infection and Compensated Cirrhosis: An Integrated Analysis.
Gastroenterology
; 152(6): 1372-1382.e2, 2017 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-28193518
3.
Elbasvir-Grazoprevir to Treat Hepatitis C Virus Infection in Persons Receiving Opioid Agonist Therapy: A Randomized Trial.
Ann Intern Med
; 165(9): 625-634, 2016 11 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-27537841
4.
Grazoprevir, Elbasvir, and Ribavirin for Chronic Hepatitis C Virus Genotype 1 Infection After Failure of Pegylated Interferon and Ribavirin With an Earlier-Generation Protease Inhibitor: Final 24-Week Results From C-SALVAGE.
Clin Infect Dis
; 62(1): 32-6, 2016 Jan 01.
Artículo
en Inglés
| MEDLINE | ID: mdl-26371152
5.
The Combination of Grazoprevir, a Hepatitis C Virus (HCV) NS3/4A Protease Inhibitor, and Elbasvir, an HCV NS5A Inhibitor, Demonstrates a High Genetic Barrier to Resistance in HCV Genotype 1a Replicons.
Antimicrob Agents Chemother
; 60(5): 2954-64, 2016 05.
Artículo
en Inglés
| MEDLINE | ID: mdl-26926625
6.
Efficacy and safety of 8 weeks versus 12 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin in patients with hepatitis C virus genotype 1 mono-infection and HIV/hepatitis C virus co-infection (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1087-97, 2015 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25467560
7.
Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial.
Lancet
; 385(9973): 1075-86, 2015 Mar 21.
Artículo
en Inglés
| MEDLINE | ID: mdl-25467591
8.
Vaniprevir plus peginterferon alfa-2b and ribavirin in treatment-experienced Japanese patients with hepatitis C virus genotype 1 (GT1b) infection: Phase 3 studies.
J Gastroenterol Hepatol
; 31(10): 1674-1683, 2016 Oct.
Artículo
en Inglés
| MEDLINE | ID: mdl-26936417
9.
Grazoprevir and elbasvir plus ribavirin for chronic HCV genotype-1 infection after failure of combination therapy containing a direct-acting antiviral agent.
J Hepatol
; 63(3): 564-72, 2015 Sep.
Artículo
en Inglés
| MEDLINE | ID: mdl-25895428
10.
Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir.
Antimicrob Agents Chemother
; 59(11): 6922-9, 2015 Nov.
Artículo
en Inglés
| MEDLINE | ID: mdl-26303801
11.
The combination of MK-5172, peginterferon, and ribavirin is effective in treatment-naive patients with hepatitis C virus genotype 1 infection without cirrhosis.
Gastroenterology
; 147(2): 366-76.e6, 2014 Aug.
Artículo
en Inglés
| MEDLINE | ID: mdl-24727022
12.
Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection.
Clin Infect Dis
; 59(12): 1657-65, 2014 Dec 15.
Artículo
en Inglés
| MEDLINE | ID: mdl-25266289
13.
Boceprevir for chronic HCV genotype 1 infection in patients with prior treatment failure to peginterferon/ribavirin, including prior null response.
J Hepatol
; 60(4): 748-56, 2014 Apr.
Artículo
en Inglés
| MEDLINE | ID: mdl-24362076
14.
Corrigendum to "Hepatitis C virus drug resistance associated substitutions and their clinical relevance: Update 2018" [Drug Resist. Updates 37 (March) (2018) 17-39].
Drug Resist Updat
; 40: 40-41, 2018 09.
Artículo
en Inglés
| MEDLINE | ID: mdl-29680499
15.
Antiviral activity of boceprevir monotherapy in treatment-naive subjects with chronic hepatitis C genotype 2/3.
J Hepatol
; 59(1): 31-7, 2013 Jul.
Artículo
en Inglés
| MEDLINE | ID: mdl-23454058
16.
Characteristics of hepatitis C virus resistance in an international cohort after a decade of direct-acting antivirals.
JHEP Rep
; 4(5): 100462, 2022 May.
Artículo
en Inglés
| MEDLINE | ID: mdl-35434589
17.
Validation of a Genotype-Independent Hepatitis C Virus Near-Whole Genome Sequencing Assay.
Viruses
; 13(9)2021 08 30.
Artículo
en Inglés
| MEDLINE | ID: mdl-34578305
18.
SHARED: An International Collaboration to Unravel Hepatitis C Resistance.
Viruses
; 13(8)2021 08 10.
Artículo
en Inglés
| MEDLINE | ID: mdl-34452444
19.
Intra-host evolutionary dynamics of the hepatitis C virus among people who inject drugs.
Sci Rep
; 11(1): 9986, 2021 05 11.
Artículo
en Inglés
| MEDLINE | ID: mdl-33976241
20.
HCV796: A selective nonstructural protein 5B polymerase inhibitor with potent anti-hepatitis C virus activity in vitro, in mice with chimeric human livers, and in humans infected with hepatitis C virus.
Hepatology
; 49(3): 745-52, 2009 Mar.
Artículo
en Inglés
| MEDLINE | ID: mdl-19072827